CARM - Carisma Therapeutics Inc
IEX Last Trade
1.06
-0.030 -2.830%
Share volume: 77,797
Last Updated: Fri 30 Aug 2024 09:59:53 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.09
-0.03
-2.75%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-08 | 2022-11-07 | 2023-02-28 | 2023-05-11 | 2023-08-10 | 2023-11-09 | 2024-04-01 | 2024-05-09 | |
| Total revenue | 0.000 | 40.000 M | 0.000 | 3.243 M | 3.560 M | 3.827 M | 4.289 M | 3.397 M | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 40.000 M | 0.000 | 3.243 M | 3.560 M | 3.827 M | 4.289 M | 3.397 M | |
| inf% | -100.00% | inf% | 9.77% | 7.50% | 12.07% | -20.80% | |||
| Operating expenses | 45.533 M | 11.072 M | 8.041 M | 26.215 M | 24.525 M | 26.171 M | 26.739 M | 22.907 M | |
| Selling general and admin | 15.589 M | 8.141 M | 7.082 M | 9.574 M | 6.007 M | 6.620 M | 7.324 M | 5.445 M | |
| Research and development | 29.944 M | 2.931 M | 959.000 K | 16.641 M | 18.518 M | 19.551 M | 19.415 M | 17.462 M | |
| Total expenses | 45.533 M | 11.072 M | 8.041 M | 26.215 M | 24.525 M | 26.171 M | 26.739 M | 22.907 M | |
| -75.68% | -27.38% | 226.02% | -6.45% | 6.71% | 2.17% | -14.33% | |||
| Operating income | -45.533 M | 28.928 M | -8.041 M | -22.972 M | -20.965 M | -22.344 M | -22.450 M | -19.510 M | |
| Ebit | -45.533 M | 28.928 M | -8.041 M | -22.972 M | -20.965 M | -22.344 M | -22.450 M | -19.510 M | |
| Pretax income | -35.835 M | 20.457 M | -7.574 M | -24.533 M | -19.788 M | -21.403 M | -21.155 M | -18.978 M | |
| -157.09% | -137.02% | 223.91% | -19.34% | 8.16% | -1.16% | -10.29% | |||
| Income tax | -3.875 M | 0.000 | 0.000 | 109.000 K | 88.000 K | 0.000 | -197.000 K | 0.000 | |
| Net income basic | -31.960 M | 20.457 M | -7.574 M | -24.642 M | -19.876 M | -21.403 M | -20.958 M | -18.978 M | |
| 164.01% | -137.02% | -225.35% | 19.34% | -7.68% | 2.08% | 9.45% | |||
| Net income | -31.960 M | 20.457 M | -7.574 M | -24.642 M | -19.876 M | -21.403 M | -20.958 M | -18.978 M | |
| 164.01% | -137.02% | -225.35% | 19.34% | -7.68% | 2.08% | 9.45% |